Vaccinum pneumococcale saccharidicum conjugatum

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F06%3A00001588" target="_blank" >RIV/60162694:G44__/06:00001588 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Vaccinum pneumococcale saccharidicum conjugatum

Popis výsledku v původním jazyce

The first conjugate pneumococcal vaccine authorized in the Czech Republic is a 7-valent vaccine coupled to diphteria CRM197 protein. It is suitable for immunization of children from 2 months to 2 years of age. Vaccine safety was tested in multiple controlled clinical studies with both healthy infants and previously non-vaccinated older children. Among most common adverse effects were reaction at the injection site and fever. Neither primary vaccination nor revaccination was associated with any general or local reactivity, with the exception of a higher incidence of temporary pain. The vaccine is indicated for use primarily against invasive diseases caused by Streptococcus pneumoniae of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F in infants and toddlers aged from 2 months to 2 years and in previously non-vaccinated children from 2 to 5 years of age (high risk patients). Other indications are acute otitis and nasopharyngeal carriage.

Název v anglickém jazyce

Vaccinum pneumococcale saccharidicum conjugatum

Popis výsledku anglicky

The first conjugate pneumococcal vaccine authorized in the Czech Republic is a 7-valent vaccine coupled to diphteria CRM197 protein. It is suitable for immunization of children from 2 months to 2 years of age. Vaccine safety was tested in multiple controlled clinical studies with both healthy infants and previously non-vaccinated older children. Among most common adverse effects were reaction at the injection site and fever. Neither primary vaccination nor revaccination was associated with any general or local reactivity, with the exception of a higher incidence of temporary pain. The vaccine is indicated for use primarily against invasive diseases caused by Streptococcus pneumoniae of serotypes 4, 6B, 9V, 14, 18C, 19F and 23F in infants and toddlers aged from 2 months to 2 years and in previously non-vaccinated children from 2 to 5 years of age (high risk patients). Other indications are acute otitis and nasopharyngeal carriage.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FN - Epidemiologie, infekční nemoci a klinická imunologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2006

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Remedia - Klinická mikrobiologie

ISSN

1211-7684

e-ISSN

—

Svazek periodika

1

Číslo periodika v rámci svazku

16

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

10

Strana od-do

27-36

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—